文献速递膀胱癌与上尿路尿路上皮癌

晚期尿路上皮癌的EGFR与HER2扩增及外显子20插入突变

Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.
PubMed 文献 · BJU Int · 2020-02-23

该研究对3753例晚期尿路上皮癌(UC)标本行全面基因组图谱分析,发现EGFR改变占4.1%、ERBB2改变占15%。EGFR外显子20插入和ERBB2外显子20插入分别占全部UC的0.7%和0.5%,这类患者更年轻、肿瘤突变负荷更低且TP53改变少见,构成一个独特的小众亚群,值得探索针对外显子20插入的抑制剂临床试验。

要点

  • 晚期UC中EGFR改变占4.1%,以扩增为主(64%),外显子20插入次之(18%)。
  • ERBB2改变占15%,扩增最常见(50%),外显子20插入占3.6%。
  • EGFR/ERBB2外显子20插入患者更年轻、TMB更低、TP53改变更少。

核心结论

  • EGFR和ERBB2改变分别见于4%和15%的晚期UC。
  • EGFRexon20ins和ERBB2exon20ins分别占全部UC的0.7%和0.5%,共同定义了一个其他驱动共现少、TMB低的小众独特亚群。

研究设计与样本

  • 对3753例晚期UC患者的肿瘤标本行基于杂交捕获的全面基因组图谱分析,覆盖180-395个基因。
  • TMB基于0.8或1.1 Mb DNA评估,以每兆碱基突变数报告。

主要发现

  • 3753例中EGFR改变154例(4.1%),其中扩增99/154(64%),外显子20插入27/154(18%)。
  • ERBB2改变552/3753例(15%),其中扩增278/552(50%),外显子20插入20/552(3.6%)。
  • EGFRexon20ins患者中位年龄62 vs 69岁(P=2.6E-2),ERBB2exon20ins患者60 vs 68岁(P=7.8E-4)。
  • EGFRexon20ins患者TMB中位3.6 vs 7.2(P=2.7E-4),ERBB2exon20ins患者2.5 vs 10(P=1.2E-7)。
  • EGFRexon20ins患者TP53改变3.7% vs 83%(P=4.3E-14),ERBB2exon20ins患者20% vs 68%(P=9.8E-4)。

临床怎么用

  • 对晚期UC患者可考虑全面基因组图谱分析以识别EGFR/ERBB2外显子20插入。
  • 鉴于非小细胞肺癌中针对外显子20插入抑制剂的 promising 临床研究,可考虑为携带此类改变的UC患者设计临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To review the genomic landscape of advanced urothelial carcinoma (UC) to assess the frequencies of EGFR and ERBB2 (HER2) alterations. MATERIALS AND METHODS: Tumour specimens from 3753 patients with advanced UC were assayed with hybrid capture-based comprehensive genomic profiling of 180-395 genes. Tumour mutational burden (TMB) was assessed on 0.8 or 1.1 Mb of DNA, and is reported as mutations per megabase. RESULTS: In 3753 cases of UC, EGFR alterations were detected in 4.1% (154) and were most commonly amplifications (64%; 99/154), while exon 20 insertions (EGFRexon20ins ) were the second most common alteration (18%; 27/154). Alterations in ERBB2 were observed in 15% (552/3753) of cases and, similarly, ERBB2 amplification was the most commonly observed alteration (278/552; 50%); ERBB2exon20ins occurred in 3.6% (20/552) of cases. EGFRexon20ins and ERBB2exon20ins occurred in younger patients (median age 62 vs 69 years, P = 2.6E-2 and 60 vs 68 years, P = 7.8E-4), and these cases had significantly lower TMB (median 3.6 vs 7.2, P = 2.7E-4 and 2.5 vs 10, P = 1.2E-7) and less frequent TP53 alterations (3.7% vs 83%, P = 4.3E-14 and 20% vs 68%, P = 9.8E-4) compared to cases with other EGFR or ERBB2 alterations. CONCLUSION: EGFR and ERBB2 alterations occur in 4% and 15% of UC, respectively. EGFRexon20ins and ERBB2exon20ins were present in 0.7% and 0.5% of UC overall and collectively define a small, but distinct, subset of UC with infrequent co-occurrence of other drivers and low TMB. Given recent promising clinical studies of inhibitors with activity against exon 20 insertions in non-small cell lung cancer, consideration should be given to developing a trial inclusive of patients with UC harbouring these alterations.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Madison RW, Gupta SV, Elamin YY, et al. Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. BJU Int. 2020. PMID: 31985116. doi:10.1111/bju.15006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。